Ashland (ASH) announced that it has signed a definitive agreement to sell its Avoca business to Mane. The transaction is expected to close in the calendar first quarter 2025, subject to the satisfaction of customary closing conditions. Ashland’s Avoca business supplies Sclareolide, a fragrance fixative, and a range of contract manufacturing capabilities from two production facilities in North Carolina and Wisconsin. The Avoca business line represents the last entity from Ashland’s previous acquisition of Pharmachem.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASH:
- Ashland price target lowered to $85 from $100 at Evercore ISI
- Ashland price target raised to $84 from $83 at BMO Capital
- Ashland price target lowered to $90 from $95 at Wells Fargo
- Ashland Announces Departure of Finance VP Eric Boni
- Ex-Dividend Date Nearing for These 10 Stocks – Week of November 25, 2024